SAGE Therapeutics downgraded by BofA Securities with a new price target

4/17/24 9:57:48 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

BofA Securities downgraded SAGE Therapeutics from Neutral to Underperform and set a new price target of $14.00 from $24.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SAGE

Date	Price Target	Rating	Analyst
3/11/2025	$5.00	Underperform	BofA Securities
11/21/2024	$4.00	Underperform → Sector Perform	RBC Capital Mkts
10/10/2024		Mkt Perform	Raymond James
10/4/2024	$10.00 → $4.00	Outperform → Sector Perform	RBC Capital Mkts
7/30/2024	$16.00 → $10.00	Buy → Hold	TD Cowen
7/25/2024	$18.00 → $12.00	Overweight → Neutral	JP Morgan
5/29/2024	$15.00	Neutral	Robert W. Baird
5/29/2024	$8.00	Sell	Citigroup